Patent Law Weblog
recent posts
- Extremity Medical, LLC v. Nextremity Solutions, Inc. (Fed. Cir. 2026)
- PTAB § 101 Affirmance Rates Dip under Director Squires
- In re Magnolia Medical Technologies, Inc. (Fed. Cir. 2026)
- Improving the Abstract Idea: How a Rhetorical Move Undermines § 101 Analysis of Technical Improvements in Software Inventions
- Melinta Therapeutics, LLC v. Nexus Pharmaceuticals, Inc. (Fed. Cir. 2026)
about
Category: Best Mode
-
By Suresh Pillai — Last week, the Federal Circuit affirmed a determination by the International Trade Commission ("ITC") that: (1) the asserted claims of U.S. Patent Nos. 5,827,698 and 6,040,160 were invalid for failure to comply with the best mode requirement, and (2) the '698 patent was unenforceable due to inequitable conduct. Both the…
-
By Kevin E. Noonan — On Friday, the Court of Appeals for the Federal Circuit handed Pfizer a mixed decision on defendant Teva’s appeal of a District Court judgment that Teva was liable for infringing a trio of Pfizer patents (U.S. Patent Nos. 5,466,823; 5,563,165; and 5,760,068) relating to the pain medication Celebrex®…
Patent Docs 